Inventor

MANLEY PAUL W

CH44 patents

⚠️ This page may combine multiple inventors who share the name “MANLEY PAUL W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MANLEY PAUL W

NOVARTIS AG

Bicyclic amides as kinase inhibitors

Phenylpyridine derivatives useful as phosphodiesterase inhibitors

4-oxy-3-(aryl)phenyl-arylcarbonyloxy compounds useful as phosphodiesterase inhibitors

Phenylpyridine derivatives useful as phosphodiesterase inhibitors

N-phenyl-2-pyrimidine-amine derivatives

Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Inhibitors of tyrosine kinases

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Combination of pyrimidylaminobenzamide compounds and imatinib for treating gastrointestinal stromal tumours

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis

Inhibitors of tyrosine kinases

Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome

Cyclic diaryl ureas suitable as tyrosine kinase inhibitors

N-phenyl-2-pyrimidine-amine derivatives

Oxazolo-and furopyrimidines and their use in medicaments against tumors

Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors

Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase

Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors

Triaryl compounds

Benzopyrans and pharmaceutical compositions containing them

Phthalazine derivatives for treating inflammatory diseases

Anthranilic acid amides and pharmaceutical use thereof

SEARLE & CO

Imidazopyridine derivatives and pharmaceutical compositions

Substituted alkylidene imidazoles

Certain 1H-imidazol-1-yl-1-lower-alkanoic acid derivatives having anti-thrombotic activity

Imidazole hydrazone and hydrazine derivatives

Heterocyclic group-containing compounds

Imidazole hydrazone derivatives

6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents

Imidazopyridine derivatives

MANLEY PAUL W

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide

Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma

Organic compounds

ALLAND LEILA

Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Pyrimidylaminobenzamide derivatives for systemic mastocytosis

DONATO NICHOLAS J

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

SANDOZ LTD

2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2H-1-benzopyrans

GRIFFIN JAMES D

Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

BOLD GUIDO

Heterobicyclic carboxamides as inhibitors for kinases